Melanoma imaging with pretargeted bivalent bacteriophage

Journal of Nuclear Medicine

Volumn 48, Issue 3, 2007, Pages 429-436

  Newton, Jessica R ^a   Miao, Yubin ^b   Deutscher, Susan L ^a,c   Quinn, Thomas P ^a,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

melanocyte stimulating hormone; 2 step imaging; Bacteriophage; Pretargeting

Indexed keywords

ALPHA INTERMEDIN; BIOLOGICAL MARKER; MELANOCORTIN RECEPTOR; PENTETIC ACID; STREPTAVIDIN; DIAGNOSTIC AGENT; INDIUM;

ANIMAL CELL; ARTICLE; BACTERIOPHAGE; BIOTINYLATION; COMPUTER ASSISTED TOMOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; MOLECULAR GENETICS; SCINTISCANNING;

ALPHA-MSH; AMINO ACID SEQUENCE; ANIMALS; BACTERIOPHAGES; BIOTINYLATION; INDIUM RADIOISOTOPES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; STREPTAVIDIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34247205399     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315-1317.
2. Landon LA, Zou J, Deutscher SL. Effective combinatorial strategy to increase affinity of carbohydrate binding by peptides. Mol Divers. 2004;8:35-50.
3. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med. 2001;7:1249-1253.
4. Peletskaya EN, Glinsky VV, Glinsky GV, Deutscher SL, Quinn TP. Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. J Mol Biol. 1997;270:374-384.
5. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
6. Karasseva N, Glinsky VV, Chen NX, Komatireddy R, Quinn TP. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem. 2002;21:287-296.
7. Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19:1978-1985.
8. Dreier B, Fuller RP, Segal DJ, et al. Development of zinc finger domains for recognition of the 5′-CNN-3′ family DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem. 2005;280:35588-35597.
9. Kelly KA, Jones DA. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia. 2003;5:437-444.
10. Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol. 2004;1:113-132.
11. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des. 2004;10:2335-2343.
12. Kelly K, Alencar H, Funovics M, Mahmood U, Weissleder R. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res. 2004;64:6247-6251.
13. Chen X, Sievers E, Hou Y, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
14. Kennel SJ, Mirzadeh S, Hurst GB, et al. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl Med Biol. 2000;27:815-825.
15. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrinol Rev. 2003;24:389-427.
16. Jaye DL, Geigerman CM, Fuller RE, Akyildiz A, Parkos CA. Direct fluorochrome labeling of phage display library clones for studying binding specificities: applications in flow cytometry and fluorescence microscopy. J Immunol Methods. 2004;295:119-127.
17. Zou J, Dickerson MT, Owen NK, Landon LA, Deutscher SL. Biodistribution of filamentous phage peptide libraries in mice. Mol Biol Rep. 2004;31:121-129.
18. Inchley CJ. The activity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol. 1969;5:173-187.
19. Siegrist W, Solca F, Stutz S, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352-6358.
20. Cone RD, Mountjoy KG, Robbins LS, et al. Cloning and functional characterization of a family of receptors for the melanotropic peptides. Ann N Y Acad Sci. 1993;680:342-363.
21. Tatro JB, Atkins M, Mier JW, et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest. 1990;85:1825-1832.
22. Smith GP. Smith lab home page. Available at: http://www.biosci.missouri. edu/smithGP/. Accessed January 18, 2007.
23. Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 2006;8:772-780.
24. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
25. Wilbur DS, Hamlin DK, Sanderson J, Lin Y. Streptavidin in antibody pretargeting. 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization. Bioconjug Chem. 2004;15:1454-1463.
26. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754-5758.
27. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol. 1999;26:687-693.
28. Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-α-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med. 2005;46:887-895.
29. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649-5658.
30. Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem. 2002;45:3048-3056.
31. Chen L, Schechter B, Arnon R, Wilchek M. Tissue selective affinity targeting using the avidin-biotin system. Drug Dev Res. 2000;50:258-271.
32. Wilbur DS, Hamlin DK, Buhler KR, et al. Streptavidin in antibody pretargeting. 2. Evaluation of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem. 1998;9:322-330.
33. Schechter B, Silberman R, Arnon R, Wilchek M. Tissue distribution of avidin and streptavidin injected to mice: effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem. 1990;189:327-331.
34. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs. 2005;19:145-163.